MANAGEMENT OF PATIENT WITH GASTROESOPHAGEAL REFLUX DISEASE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents modern data on prevalence, basic mechanisms of development and tactics of conducting patients with gastroesophageal reflux disease (GERD). Effectiveness of primary and maintenance therapy with proton pump inhibitors (PPI) was analyzed. Author demonstrates the role of kinetic disorders and especially the composition of reluctate, in particular the presence of duodenal contents, in the lack of effectiveness of treatment of patients with GERD. The necessity of adding to antisecretory therapy PPI and prokinetics drugs ursodesoxycholic-howling acid for the correction of these pathogenetic mechanisms is justified.

Full Text

Restricted Access

About the authors

Yelena Yurevna YEREMINA

N.P. Ogarev Mordovia State University

Email: eeu610mail.ru
MD, Professor, Head of the Department of Internal Medicine Propaedeutics; the Chief gastroenterologist of Ministry of Health of the Mordovia Republic 430005, Republic of Mordovia, Saransk, 68 Bolshevistskaya St

References

  1. Гастроэнтерология. Национальное руководство. Под ред. В.Т. Ивашкина, Т.Л. Лапиной. М.:ГЭОТАР-Медиа, 2008
  2. Гастроэнтерология. Национальное руководство. Под ред. В.Т. Ивашкина, Т.Л. Лапиной. М.:ГЭОТАР-Медиа, 2008
  3. Стандарты диагностики и лечения кислотозависимых и ассоциированных с Helicobacter pylori заболеваний (4-е Московское соглашение). Экспериментальная и клиническая гастроэнтерология. 2010;5:113-8
  4. Трухманов А.С., Джахая Н.Л., Кайбышева В.О., Сторонова О.А. Новые аспекты рекомендаций по лечению больных гастроэзофагеальной рефлюксной болезнью. Гастроэнтерология и гепатология. 2013;2:2-9
  5. Vakil N., van Zanden S.V., Kahrilas P.J., Dent J., Jones R. The Montreal definition and classification of gastroesophageal reflux disease: A global evidence-based consensus. Am. J. Gastroenterol. 2006;101 (8) :1900-20.
  6. Ивашкин В.Т., Маев И.В., Трухманов А.С. и др. Гастроэзофагеальная рефлюксная болезнь. Клинические рекомендации. РГА. 2014. 23 с.
  7. Jones R., Junghard O., Dent J., Vakil N., Halling K., Wernersson B., Lind T. Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care. Aliment Pharmacol. Ther. 2009;30(10):1030-8.
  8. Hershcovici T., Fass R. Gastro-oesophageal reflux disease: beyond proton pump inhibitor therapy. Drugs. 2011 ;71 (18):2381 -9.
  9. Katz P.O., Gerson L.B., Vela M.F. Guidelines for the diagnosis and management of GERD. Am. J. Gastroenterol 2013; 108:308-28.
  10. Allaix M.E., Patti M.G. Current status of diagnosis and treatment of GERD in the US. Minerva Gastroenterol. Dietol. 2013;59(1 ):41 -8.
  11. Fass R. Non-erosive reflux disease (NERD) and erosive esophagitis - a spectrum of disease or special entities? Z. Gastroenterol. 2007;45(11):1156-63.
  12. Fletcher J., Wirz A., Young J., Vallance R., McColl K.E. Unbuffered highly acadic gastric juice exist at the gastroesophageal function after a meal. Gastroenterology. 2001 ;121 (4):775-83.
  13. Бордин Д.С., Колбасников С.В. Патогенетические основы развития гастроэзофагеальной рефлюксной болезни. Диагностика и лечение. Вестник семейной медицины. 2013;1:30-4.
  14. Dent J., El-Serag H.B., Walander M.A., Johansson S. Epidemiology of gastro-esophageal reflux disease: a systematic review. Gut. 2005;54(4):710-7.
  15. Лазебник Л.Б., Машарова А.А., Бордин Д.С. и др. Результаты Многоцентрового исследования «Эпидемиология Гастроэзофагеальной Рефлюксной болезни в России (МЭГРЕ)». Терапевтический архив. 2011;1:45-50.
  16. Зверева С.И. Распространенность и особенности клинических проявлений гастроэзофагеальной рефлюксной болезни в республике Мордовия (по данным исследования МЭГРЕ). Экспериментальная и клиническая гастроэнтерология. 2010;9:9-14
  17. Еремина Е.Ю., Зверева С.И. Результаты многоцентрового эпилемиологического исследования распространенности гастроэзофагеальной рефлюксной болезни по г. Саранску. Медицинский альманах. 2009;6:53-5
  18. Sandu M., Barboi O., Drug V., et al. Gastroesophageal reflux disease in respiratory disorders. J. Gastroenterol. Hepatol. 2013;28 (Suppl. 3):513.
  19. Xuan Jiang, Yan H., Peng X., et al. Study on the characteristics of gastroesopheal reflux disease overlap with functional bowl diseases in GI clinic. J. Gastroenterol. Hepatol. 2013;28(Suppl. 3):511.
  20. Greenspan N.R. Gastroesophageal reflux disease: endoscopy, duration of treatment and choice of PPI. Med. Health R. I. 2011 ;94(4):92-4.
  21. Буеверов А.О., Лапина Т.Л. Дуоденогастроэзофагеальный рефлюкс как причина рефлюкс-эзофагита. Фарматека. 2006;1:1-5.
  22. Mabrut J.U., Colland J.M., Baulieux J. Duodenogastric and gastroesophageal bile reflux. J. Chir.(Paris). 2006;143(6) :355-65.
  23. Лапина Т.Л., Буеверов А.О. Горечь во рту: интерпретация гастроэнтеролога. Клин. перспективы гастроэнтерологии, гепатологии. 2013;3:18-24
  24. Kircheiner J., Glatt S., Fuhr U., Klotz U., Meineke I., Seufferlein T., Brockmöller J. Relative potency of proton-pump inhibitors -comparison of effects on intragastric pH. Eur. J. Clin. Pharmacol. 2009;65:19-31.
  25. Edwards J., Lind T., Lundell L.T., Das R. Systematic reviev standard and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis - a mixed treatment comparison of randomuced controlled trials. Aliment. Pharmacol. Ther 2009;30:547-56.
  26. Katz P.O., Ginsberg G.G., Hoyle P.E., Sostek M.B., Monyak J.T., Silberg D.G. Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis. Aliment. Pharmacol. Ther. 2007;25:617-28.
  27. Sachs G., Shin J.M., Vagin O., Lambrecht N., Yakubov I., Munson K. The gastric H,K-ATPase as a drug target: past, present, and future. J. Clin. Gastroenterol. 2007 ;41 (Suppl. 2):226-42.
  28. Mayer M.D., Vakily M., Witt G., Mulford D.J. The pharmacokinetics of TAK-390 MR 60 mg, a dual delayed release formulation of the proton pump inhibitor TAK-390, and lansoprazole 60 mg: a retrospective analysis. Gastroenterology. 2008;134(4 Suppl. 1 ) :A176.
  29. Kukulka M. Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg. Clin. Exp. Gastroenterol. 2011 ;4:213-20.
  30. Philip O., Katz P.O., Louren B., Gerson L.B., Marcelo F., Vela M.F. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am. J. Gastroenterol. 2013;108:308-28.
  31. Huber R., Hartmann M., Bliesath H., Lühmann R., Steinijans V.W., Zech K. Pharmacokinetics of pantoprazole in man. Intern. J. Clin. Pharmacol. Ther. 1996;34(5):185-94.
  32. Wedemeyer R., Blume H. Pharmacjkinetic drug interaction profiles of proton pump inhibitors an update. Drug Saf. 2014; 37(4) :201 -11
  33. Atmaca M., Ozturk M., Yildiz S. et al. Pantoprazole may improve beta cell function and diabetes mellitus. J. Endocrinol. Invest. 2014;37(5):449-54.
  34. González-Ortiz M., Martinez-Abundis E., Mercado-Sesma A.R., Álvarez-Carrillo R. Effect of pantoprazole on insulin secretion in drug-naive patients with type 2 diabetes. Diabetes Res. Clin. Pract. 2015;108(1 ) :e11 -3.
  35. Andersson Т., Rohss K., Hassan-Alin M., Bredberg E. Pharmacokinetics and dose-response relationship of esomeprasole. Gastroenterology. 2000; 118:A1210.
  36. Rohss K., Wilder-Smith C., Claar-Nilsson С. et al. Esomeprazole 40 mg provides more effective acid control than standard doses of all other proton pump inhibitors. Gastroenterology. 2001 ; 120:A2140.
  37. Wilder-Smith C., Rohss K., Lundin C., Rydholm H. Esomeprazole 40 mg provides more effective acid control than pantoprazole 40 mg. Gastroenterology. 2000;118:A22.
  38. Castell D., Castell D., Kahrilas P. et al. Esomeprazole provides more effective healing than lansoprazole in GERD patients with erosive oesophagitis. Gut. 2001 ;49(Suppl.):A3363.
  39. Edwards S., Lind Т., Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux eosophagitis. Aliment. Pharmacol. Ther. 2001 ;15:1729-36.
  40. Kahrilas P., Falk J., Johnson D. et al. Esomeprazole improves healing and symptom reso-lution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment. Pharmacol. Ther. 2000;14:1249-58.
  41. Richter J., Kahrilas P., Johanson J. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive oesophagitis: a randomized controlled trial // Amer. J. Gastroenterol. 2001 ;96: 656-65.
  42. Galmiche J.P., Hatlebakk J., Attwood S., Ell C., Ell C., Fiocca R., Eklund S., Langström G., Lind T., Lundell L. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA. 2011;305:1969-77.
  43. Nehra D. Composition of the refluxate in Barrett esophagus. Paris: John Libbey Eurotext. 2003;1:18-21.
  44. Xu X.R., Li Z.S., Zou D.W., Xu G.M., Ye P., Sun Z.X., Wang Q., Zeng Y.J. Role of duodenogastroesophageal reflux in the pathogenesis of esophageal mucosal injury and gastroesophageal reflux symptoms. Can. J. Gastroenterol. 2006;20:91 -4.
  45. Kunsch S., Neesse A., Schroder W. Prospective evaluation of dudenogastroesophageal reflux in gastroesophageal reflux disease patients refractory to protein pump inhibitor therapy. Digestion. 2012;86:315-22.
  46. Sifrim D., Holloway R. Transient lower esophageal spchinter relaxations: how many or how harmful? Am. J. Gastroenterol. 2001 ;96(9):2529-32.
  47. Eun Hye Kim, Lee D., Park K. et al. Evaluation of efficacy of proton pump inihibitors in refractory gastroesophageal reflux disease. J. Gastroenterol. Hepatol 2013; 28(Suppl. 3):290.
  48. Richter J.E. Duodenogastric reflux-induced (alkaline) esophagitis. Curr. Treat Options Gastroenterol. 2004;7:53-8.
  49. Mushiroda T., Douya R., Takahara E. et al. The involvement of flavin-containing monooxygenase but not CYP3 A4 in metabolism of itopride hydrochloride, a gastroprokinetic agent: comparison with cisapride and mosapride citrate. Drug Metabol. Dispos. 2000;28:1231-37.
  50. Scarpellini E., Vos R., Blondeau K., Boecxstaens V., Farré R., Gasbarrini A., Tack J. The effects of itopride on oesophageal motility and lower oesophageal sphincter function in man. Aliment. Pharmacol. Ther. 2011 ;33;1:99-105.
  51. Tack J. Prokinetics and fundic relaxants in upper functional GI disorders. Curr. Opion Pharmacol. 2008;8(6):690-6.
  52. Звенигородская Л.А., Чурикова А.А. Гастроэзофагеальная рефлюксная болезнь у пожилых больных. Фарматека. 2012 ;4(243) :23-5.
  53. Маев И.В, Дичева Д.Т., Андреев Д.Н. Подходы к индивидуализации лечения гастроэзофагеальной рефлюксной болезни. Гастроэнтерология. 2012;4:1-5

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies